On Thursday, Kellogg Company (NYSE:K)’s shares declined -0.02% to $62.26.
Kellogg Company (K) has improved its Family Rewards Program as part of its sales boosting initiative. Members will no longer have to enter the product codes while buying, thus making the shopping experience easier.
Moreover, other U.S. Kellogg brands are now participating in Kellogg’s Family Rewards. These brands comprise Pringles, Murray and Murray Sugar Free cookies, Kellogg’s Origins cereal, Keebler Ready Crusts pie crusts, and Cheez-It Crunch’D.
Kellogg’s Family Rewards Program is an important part of the company’s sales boosting strategy. It drives customer engagement with and loyalty toward the brands they buy. Per market research firm Nielsen, more than 60% of U.S. households base their purchase decisions on the loyalty programs offered by the company.
The research also reveals that customers find it difficult to redeem the points on their loyalty cards. This has been duly addressed by Kellogg’s loyalty program. The upgraded technology will link Kellogg’s Family Rewards with U.S. retailer frequent shopper cards and add the points to the respective cards, thereby eliminating the need for codes.
Kellogg has been struggling to grow sales over the past two years, mainly due to weak performance by cereals in its developed markets and U.S. snacks businesses as a result of lower demand.
Kellogg Company, together with its auxiliaries, manufactures and markets ready-to-eat cereal and convenience foods. The company operates through U.S. Morning Foods, U.S. Snacks, U.S. Specialty, North America Other, Europe, Latin America, and Asia Pacific segments. Its principal products comprise ready-to-eat cereals and convenience foods, such as cookies, crackers, savory snacks, frozen foods, toaster pastries, cereal bars, fruit-flavored snacks, frozen waffles, and veggie foods, in addition to health and wellness business bars, and beverages.
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)’s shares gained 5.64% to $2.81.
Ampio Pharmaceuticals Inc (AMPE) a Colorado corporation and about 81.5%-owned partner of Ampio Pharmaceuticals, a Delaware corporation (the “Company”), reached and closed on an Asset Purchase Agreement (the “Purchase Agreement”) with Jazz Pharmaceuticals, Inc. (the “Seller”). Following the Purchase Agreement, Rosewind purchased from the Seller assets related to the Seller’s product known as ProstaScint (capromab pendetide), counting certain intellectual property and contracts, and the product approvals, inventory and work in progress (collectively, the “ProstaScint Business”), and assumed certain of the Seller’s liabilities, counting those related to product approvals and the sale and marketing of ProstaScint.
Rosewind paid $1.0 million at closing for the ProstaScint Business. Rosewind has also agreed to pay to the Seller an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory and $226,523 payable on September 30, 2015 (which represents a portion of certain United States Food and Drug Administration fees). Rosewind also will pay to the Seller eight percent (8%) on net sales made after October 31, 2017, payable up to a maximum aggregate payment of $2.5 million.
The Purchase Agreement contains customary representations and warranties and covenants by each party. The Purchase Agreement contains customary indemnification provisions by each party, counting, subject to certain limitations, the indemnification by each party for any losses arising out of any breach of the other party’s representations or warranties or any breach or failure to perform any of its covenants under the agreement, in addition to any liabilities arising out of the ProstaScint Business prior to the closing (as to Rosewind) and after the closing (as to the Seller).
The Purchase Agreement also provides that for a period of one year the Seller agrees to not directly or indirectly, through any of its agents or associates,
(i) compete against the ProstaScint Business, or (ii) acquire a company or business in which more than fifteen percent (15%) of such attained business’ total revenue is generated by products that compete with the ProstaScint Business.
The foregoing summary of the material terms of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement, which is being filed as an exhibit to Rosewind’s Current Report on Form 8-K on May 27, 2015, and is incorporated by reference into this Current Report on Form 8-K.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the accessible phosphate needed for the inflammation process; and decreasing vascular permeability.
At the end of Thursday’s trade, Lions Gate Entertainment Corp. (USA) (NYSE:LGF)‘s shares surged 3.91% to $35.12.
Just in time for the 50th anniversary of the worldwide box office blockbuster The Sound of Music, Lionsgate (LGF), a premier next generation global content leader, has attained all U.S., Canadian and UK distribution rights to Tele Munchen Group’s The von Trapp Family — A Life of Music, the two companies declared recently.
Award-winning Dutch filmmaker Ben Verbong, who has earned acclaim with family films such as The Girl with the Red Hair, The Slurb and Mr. Bello, is directing, and Eliza Bennett (Broadchurch, Nanny McPhee), Matthew Macfadyen (Anna Karenina, Three Musketeers) and Academy Award® nominee Rosemary Harris (Spider-Man 1-3, Tom & Viv) are starring in the film presently being shot in Salzburg and surroundings in addition to Bavaria.
The von Trapp Family has been cherished by generations of fans ever since The Sound of Music conquered global audiences and earned five Academy Awards in the 1960’s. One of the most successful motion pictures of all time, the film will celebrate its 50th anniversary this year with the release of The von Trapp Family – A Life of Music, based on Agathe von Trapp’s autobiography “Memories Before and After the Sound of Music,” which tells the story behind the legend. The screenplay was written by Christoph Silber (Good Bye Lenin) and Tim Sullivan (Letters to Juliet)
Lions Gate Entertainment Corp. engages in motion picture production and distribution, television programming and syndication, home entertainment, family entertainment, digital distribution, channel platforms, and international distribution and sales activities. The company operates through two segments, Motion Pictures and Television Production.
Plug Power Inc (NASDAQ:PLUG), ended its Thursday’s trading session with -3.01% loss, and closed at $2.73.
Plug Power Inc (PLUG) a leader in providing clean, reliable energy solutions celebrates the last stop on its milestone Plug POWERTrip, a six-city road show intended to present the Company’s success to its investment community. Plug Power will host guests at the Willard InterContinental for presentations delivered by CEO Andy Marsh and General Counsel Gerry Conway. The Plug POWERTrip also welcomes remarks from special guest US Congressman Chris Gibson.
Congressman Chris Gibson represents the people of New York’s 19th Congressional District, counting many employees at Plug Power. Throughout his Congressional career, Congressman Gibson has been a fervent supporter of fuel cells and hydrogen technologies. Through bi-partisan leadership as a member of Congress, Gibson demonstrates his understanding of what it takes to make a clean energy business successful in upstate New York.
Plug Power Inc., an alternative energy technology provider, engages in the design, development, manufacture, and commercialization of fuel cell systems for the industrial off-road markets worldwide. It focuses on proton exchange membrane (PEM) fuel cell and fuel processing technologies, and fuel cell/battery hybrid technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
